An interventional study of iCardia4HF in Heart Failure, sponsored by University of Illinois at Chicago. Completed at 1 site in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by University of Illinois at Chicago · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 2,159 studies in Heart Failure with a site in United States — 346 open to participants now, 439 under way, 27 of them phase 3. Heart Failure · United States.
Among the 2,159 studies in Heart Failure with a site in United States, this one is the 1,131st largest by enrollment of the 1,602 interventional ones that give a count, is one of 92 that started in 2019, is one of 887 with no phase, and was the 1,293rd registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →346 of the 2,159 studies in Heart Failure with a site in United States are open now. Recruiting first, the newest first:
Bettina Mittendorfer · Sites in United States
Ages 18–100 · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 18–80
AnaCardio AB · Sites in United States, Bulgaria, Canada and 5 more countries
Ages 18–85
Weill Medical College of Cornell University · Sites in United States
Ages 18+ · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 18–80 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
2,159 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 174 · Phase 2 313 · Phase 3 177 · Phase 4 139
First in 1983; this study’s year is marked. 92 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 27 is below the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 66 across the 1,602 interventional studies, 150 across the 552 observational. Of the 1,510 that completed or were terminated, 630 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
747 of 2,159 have an industry lead sponsor. The 10 most frequent:
University of Illinois at Chicago is the lead sponsor of 496 studies on the registry; 115 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 19 (59%) have results posted.
University of Illinois at Chicago has 9 studies filed under Heart Failure — fewer than ten, so there is no comparison to draw.
138 of the studies in Heart Failure with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02901184Phase 3Uppsala UniversitySpironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction | 2026-12 |
| NCT06307652Phase 3AstraZenecaStudy to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | 2027-04-16 |
| NCT06736574Phase 3CytokineticsStudy With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | 2027-09 |
| NCT06024746Phase 3Colorado Prevention CenterA Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF) | 2027-11 |
| NCT06008197Phase 3Colorado Prevention CenterA Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients | 2027-11 |
Add all 138 to your calendar (.ics) → With an account.
Among the 2,159 studies in Heart Failure with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Approximately 6.5 million people have heart failure (HF) in the United States, and 960,000 new cases are reported each year. HF is one of the most common hospital diagnosis among older adults. About 40% of patients are readmitted within 1-year following their first admission for HF and hospitalization accounts for approximately 80% of the costs of HF management. This pilot study aims to assess the feasibility, acceptability, and preliminary efficacy of a patient-centered mobile health (mHealth) technology intervention in older adults with chronic heart failure.
This is a single site, two-arm, pilot randomized controlled trial that aims to examine the feasibility, acceptability and preliminary efficacy of a mobile phone-based intervention compared to usual care in older adult patients with HF (≥50 years). Forty (n=40) patients from the University of Illinois Hospital \& Health Sciences system will be enrolled in the study, randomly assigned to the intervention or usual care group, and followed for 60 days. Patients in the intervention group will receive the Heart Failure Health Storylines mobile app developed by Self Care Catalysts in collaboration with the Heart Failure Society of America, three connected health devices from Fitbit and Nokia that interface with the mobile app, and tailored text-messages targeting health beliefs, self-care efficacy, and knowledge about HF. The control group will receive standard care which involves patient education and outpatient follow up with physical and laboratory examinations as needed. The primary study outcome is change in self-care and quality of life. Secondary outcomes include hospital re-admissions and emergency room visits.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be using a heart failure mobile app, wearable activity tracking device, Bluetooth-enabled blood pressure monitor and weight scale for self-monitoring, and receive tailored text-messages about self-care.
Behavioral: iCardia4HF
Participants assigned to the usual care group will receive standard medical care, which includes nurse-led patient education about HF self-care before discharge, and follow-up visits at the UI Health, outpatient Heart Failure program.
Participants in the intervention group will receive the Heart Failure Health Storylines mobile app, three connected health devices that interface with the app (Fitbit Charge 2 activity tracker, and FDA-approved Nokia BP monitor and Cardio Body weight scale), and a program of tailored self-care text-messages, in addition to usual care. Participants will be asked to use the app and devices to record and self-monitor their daily symptoms, blood pressure, weight, and physical activity.
Mean Change in Self-care at 30 and 60 Days
Self-care was measured with the Self-Care Heart Failure Index (SCHFI version 7.2) which includes 4 subscales: maintenance, symptom perception, management, and self-efficacy. Each scale is scored separately. Standardized scores in each scale range from 0 to 100. Higher scores indicate better self-care. Note: According to the original protocol, we had planned to use SCHFI version 6.2 which had 3 subscales (maintenance, management, and self-efficacy). However, a newer version (SCHFI v 7.2) became available before the start of the study, and we decided to use the new version.
Time frame: Baseline, 30 and 60 days
Change From Baseline in Health-related Quality of Life (HRQoL) at 30 and 60 Days
Self-reported Health-related Quality of Life was measured with the Kansas City Cardiomyopathy Questionnaire (KCCQ-12). KCCQ has four domains: Physical limitation, Symptom frequency, Quality of life, and Social Limitation. An overall summary score is calculated as the average of all four domains. Scores in each domain range from a 0-to-100 points. Lower scores represent worse health status and higher scores indicate better health status. The results below present the mean difference from baseline to 30 days and to 60 days. Positive numbers indicate improvement in health status scores, while negative numbers indicate worsening of health status scores from baseline.
Time frame: Baseline, 30 and 60 days
Hospitalizations
Number of unplanned hospitalizations due to any cause during the study (recorded from the electronic medical record and patient self-reports)
Time frame: 60 days
ER Visits
Emergency room visits (tracked from the electronic medical record and patient self-reports)
Time frame: 60 days
| Milestone | iCardia4HF | Control Group |
|---|---|---|
| Started | 13 | 14 |
| Completed | 11 | 14 |
| Not completed | 2 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Ineligible, admitted to a nursing home | 1 | 0 |
Self-care was measured with the Self-Care Heart Failure Index (SCHFI version 7.2) which includes 4 subscales: maintenance, symptom perception, management, and self-efficacy. Each scale is scored separately. Standardized scores in each scale range from 0 to 100. Higher scores indicate better self-care. Note: According to the original protocol, we had planned to use SCHFI version 6.2 which had 3 subscales (maintenance, management, and self-efficacy). However, a newer version (SCHFI v 7.2) became available before the start of the study, and we decided to use the new version.
| score on a scale | iCardia4HF | Control Group |
|---|---|---|
| Maintenance at 30 Days | 6.14 ± 15.39 | -3.39 ± 18.16 |
| Maintenance at 60 Days | 6.36 ± 15.34 | 3.75 ± 12.51 |
| Symptom Perception at 30 Days | 6.82 ± 10.04 | 6.73 ± 22.61 |
| Symptom Perception at 60 Days | 7.83 ± 9.85 | 4.37 ± 10.93 |
| Management at 30 Days | 5.19 ± 14.59 | -7.64 ± 14.07 |
| Management at 60 Days | 5.19 ± 20.14 | 1.19 ± 11.77 |
| self-efficacy at 30 Days | 5.68 ± 13.92 | -1.10 ± 12.20 |
| self-efficacy at 60 Days | 7.50 ± 17.21 | -2.50 ± 12.33 |
Self-reported Health-related Quality of Life was measured with the Kansas City Cardiomyopathy Questionnaire (KCCQ-12). KCCQ has four domains: Physical limitation, Symptom frequency, Quality of life, and Social Limitation. An overall summary score is calculated as the average of all four domains. Scores in each domain range from a 0-to-100 points. Lower scores represent worse health status and higher scores indicate better health status. The results below present the mean difference from baseline to 30 days and to 60 days. Positive numbers indicate improvement in health status scores, while negative numbers indicate worsening of health status scores from baseline.
| score on a scale | iCardia4HF | Control Group |
|---|---|---|
| Mean Change in Physical Limitation at 30 Days | 20.08 ± 27.44 | -1.64 ± 36.51 |
| Mean Change in Symptom Frequency at 30 Days | 6.25 ± 36.38 | 5.62 ± 28.90 |
| Mean Change in Quality of Life at 30 Days | 7.95 ± 31.76 | 3.53 ± 20.99 |
| Mean Change in Social Limitation at 30 Days | 14.96 ± 31.34 | -5.45 ± 25.71 |
| Mean Change in Overall Summary Score at 30 Days | 12.61 ± 23.82 | 0.12 ± 22.80 |
| Mean Change in Physical Limitation at 60 Days | 25.38 ± 22.86 | 12.50 ± 28.50 |
| Mean Change in Symptom Frequency at 60 Days | 11.93 ± 29.18 | 3.13 ± 26.86 |
| Mean Change in Quality of Life at 60 Days | 11.36 ± 24.66 | 11.61 ± 20.49 |
| Mean Change in Social Limitation at 60 Days | 13.07 ± 31.07 | -5.36 ± 32.46 |
| Mean Change in Overall Summary Score at 60 Days | 15.74 ± 22.93 | 5.47 ± 21.81 |
Number of unplanned hospitalizations due to any cause during the study (recorded from the electronic medical record and patient self-reports)
| number of hospitalizations | iCardia4HF | Control Group |
|---|---|---|
| Hospitalizations | 4 | 2 |
Emergency room visits (tracked from the electronic medical record and patient self-reports)
| Number of ER visits | iCardia4HF | Control Group |
|---|---|---|
| ER Visits | 2 | 2 |
Collected over 60 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| iCardia4HF | 0/11 (0%) | 3/11 (27.3%) | 0/11 (0%) |
| Control Group | 0/14 (0%) | 1/14 (7.1%) | 0/14 (0%) |
| Event | iCardia4HF | Control Group |
|---|---|---|
| Acute Decompensated Chronic Heart FailureCardiac disorders | 1/11 | 0/14 |
| Internal HemorrhoidsGastrointestinal disorders | 1/11 | 0/14 |
| Armpit abscessInfections and infestations | 1/11 | 0/14 |
| branched retinal artery occlusionEye disorders | 1/11 | 0/14 |
| Diarrhea with Uncertain CauseGastrointestinal disorders | 1/11 | 0/14 |
| Chest painCardiac disorders | 0/11 | 1/14 |
| Age, Categorical(Participants) | iCardia4HF | Control Group | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 8 | 12 | 20 |
| >=65 years | 3 | 2 | 5 |
| Age, Continuous(years) | iCardia4HF | Control Group | Total |
|---|---|---|---|
| Mean | 55.4 ± 9.17 | 56.4 ± 7.8 | 56 ± 8.3 |
| Sex: Female, Male(Participants) | iCardia4HF | Control Group | Total |
|---|---|---|---|
| Female | 6 | 5 | 11 |
| Male | 5 | 9 | 14 |
| Race (NIH/OMB)(Participants) | iCardia4HF | Control Group | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 10 | 13 | 23 |
| White | 1 | 1 | 2 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | iCardia4HF | Control Group | Total |
|---|---|---|---|
| United States | 11 | 14 | 25 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2019 to primary completion in Feb 2020, 12 months.
Results were first posted in Oct 2026, 6 years 7 months after primary completion.
Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's 12 months is below that.
Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Illinois at Chicago →